Integra LifeSciences Receives FDA Clearance for Expanded Indication for Spinal Device
Integra LifeSciences Holdings Corporation (Nasdaq: IART) today announced that the Food and Drug Administration (FDA) has approved an expanded indication for use of the Integra® Vu aPOD™ Prime Intervertebral Body Fusion Device (IBD) in anterior lumbar interbody fusion (ALIF) procedures. The new stand-alone indication includes four points of fixation, which is composed of two screws and a SpinPlate™. The Integra® Vu aPOD™ Prime IBD will be featured at the Congress of Neurological Surgeons (CNS) annual meeting, October 6 – 10, 2012, in Chicago, Illinois.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.